Poster: Novel AAV Enhancer for Improved Viral Titers and Reduced Production Costs Across Suspension HEK Platforms

In recent years, there has been an exponential increase in the number of registered clinical trials examining the use of recombinant adeno-associated virus (AAV)-based gene therapies. Upstream production of AAV therapies is often driven by transient transfection of suspension HEK cells with multiple plasmid DNA constructs encoding essential virus proteins. AAV therapies require high titers of viral genomes per dosage, prompting the need for more efficient methods of AAV manufacturing to reduce overall costs. Accordingly, methods to improve AAV titers and quality have broad implications for the economical manufacturing of high dose assets and mainstream utilization for AAV gene editing.

Download the full poster now to learn about the RevIT™ AAV Enhancer.